IP Library Granted Patent US 8,563,050
Granted Patent B2
US 8,563,050 · App. 13/254,632 · Granted Oct 22, 2013

Pharmaceutical composition containing a fermented, dehydrated material with amorphous crystalline structure

Inventor: Máté Hidvégi (Budapest, HU)
Assignees: Máté Hidvégi; BIROPHARMA Elso Magyar Biotechnologiai Kft.; TAPSZER Elelmiszeripari Gyarto és Kereskedelmi Kft.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,563,050
App. No.
13/254,632
Granted
Oct 22, 2013
Kind
B2
Abstract

The invention concerns a high water soluble product, containing a dehydrated material, obtained by fermenting wheat germ in aqueous medium in the presence of microorganisms of the Saccharomyces genus, forming amorphous crystal structure with inert auxiliary materials), commonly used in preparation of drugs. The invention also relates to the production process of said products, to immunostimulatory, immunomodulatory, antitumor and cardiovaskular pharmaceutical preparations containing them, and to the therapeutic methods for their use.

Claims (18)

1. A method for the treatment of cancer, which comprises administering to a human an effective amount of a pharmaceutical preparation comprising as an active ingredient

a high water soluble, amorphous dehydrated product, obtained by fermenting wheat germ in an aqueous medium in the presence of microorganisms of the Saccharomyces genus, and

a) concentrating and cooling the thus resulted fermentation liquid, and adding to the resulted fermentation liquid 0.1-5% (w/w) taste improving material(s) and optionally surfactant(s) and other auxiliary material(s), dissolved in water and lyophilizing the mixture thus obtained, or

b) cooling the thus resulted fermentation liquid, and adding to the resulted fermentation liquid 0.1-5% (w/w) taste improving material(s) and optionally surfactant(s) and other auxiliary material(s), dissolved in water, and concentrating and lyophilizing the mixture thus obtained,

and optionally pharmaceutical auxiliary materials.

2. The method for the treatment of cancer according to claim 1 , wherein the surfactants are surface-stabilizing, dispersing or emulsifying agents.

3. The method for the treatment of cancer according to claim 1 , wherein the surfactants are selected from the group consisting of at least one of polyoxyethylene alkyl ethers, polyoxyethylene sorbitane fatty acid esters, polyethylene glycols, sodium dodecyl sulfate, sodium lauryl sulfate, polyvinylpyrrolidone, block copolymers of ethylene oxide and propylene oxide, acrylic acid polymers, phosphatides, phospholipids and chitosan.

4. The method for the treatment of cancer according to claim 3 , wherein the phosphatides are lecithin.

5. The method for the treatment of cancer according to claim 1 , wherein the taste improving material(s) are selected from at least one of the group consisting of natural sweeteners and artificial sweeteners, and different flavoring compounds.

6. The method for the treatment of cancer according to claim 5 , wherein the natural sweeteners and artificial sweeteners are selected from the group consisting of at least one of Stevia and mono ammonium glycyrrhizinate, and wherein the different flavoring compounds are selected from the group consisting of at least one of fruit extracts, menthol, sweet fennel oil, and citric oil.

7. The method for the treatment of cancer according to claim 6 , wherein the Stevia is Stevia rebaudiana extracts.

8. The method for the treatment of cancer according to claim 1 , wherein the pharmaceutical preparation is formulated as a tablet, coated tablet, extended release tablet, dragée, granule, sachet, capsule, solution, suspension, emulsion, spray, suppository, ointment, patch, or liposome.

9. The method for the treatment of cancer according to claim 1 , wherein the microorganisms of the Saccharomyces genus are microorganisms from Saccharomyces cerevisiae.

10. A method for the treatment of cancer, which comprises administering to a human an effective amount of a pharmaceutical preparation comprising as an active ingredient a high water soluble, amorphous dehydrated product, obtained by fermenting wheat germ in an aqueous medium in the presence of the microorganisms of Saccharomyces cerevisiae , and

a) concentrating and cooling the thus resulted fermentation liquid, and adding to the resulted fermentation liquid 0.1-5% (w/w) Stevia natural sweetener as taste improving material(s) and optionally surfactant(s) and other auxiliary material(s), dissolved in water and lyophilizing the mixture thus obtained, or

b) cooling the thus resulted fermentation liquid, and adding to the resulted fermentation liquid 0.1-5% (w/w) Stevia natural sweetener as taste improving material(s) and optionally surfactant(s) and other auxiliary material(s), dissolved in water, and concentrating and lyophilizing the mixture thus obtained,

and optionally adding pharmaceutical auxiliary materials.

11. The method for the treatment of cancer according to claim 10 , which comprises administering to a human an effective amount of a pharmaceutical preparation containing 99.00-99.6% (w/w) fermented wheat germ freeze dried extract and 0.4-1% (w/w) Stevia natural sweetener as the taste improving material.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2013
From: HIDVEGI, MATE
To: HIDVEGI, MATE; BIROPHARMA ELSO MAGYAR BIOTECHNOLOGIAI KFT.; TAPSZER ELELMISZERIPARI GYARTO ES KERESKEDELMI KFT.
Reel/Frame 031235/0262 →
LICENSE Recorded Sep 18, 2013
From: HIDVEGI, MATE, DR.; BIROPHARMA ELSO MAGYAR BIOTECHNOLOGIAI KFT.; TAPSZER ELELMISZERIPARI GYARTO ES KERESKEDELMI KFT.
To: BIROPHARMA ELSO MAGYAR BIOTECHNOLOGIAI KFT.
Reel/Frame 031235/0299 →
Priority Claims (1)
HU 0900614 · Sep 29, 2009 · national
Continuity (2)
Provisional Application 61209200 · Mar 3, 2009
Related Publication 20120003302A1 · Jan 5, 2012